The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat

Pediatric Diabetes

Volumn 5, Issue 1, 2004, Pages 3-9

  Popovic, Jadranka ^a   Kover, Karen L ^a   Moore, Wayne V ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune diabetes; FTY720; Prevention

Indexed keywords

FINGOLIMOD; IMMUNOMODULATING AGENT; T LYMPHOCYTE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BREEDING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; HISTOPATHOLOGY; INSULITIS; LYMPHOCYTE DEPLETION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; PROPYLENE GLYCOLS; RATS; RATS, INBRED BB; SPHINGOSINE; SURVIVAL ANALYSIS;

EID: 1842832870     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-543X.2004.00036.x     Document Type: Article

References (23)

1. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000: 164: 5761-5770.
2. Quesniaux V, Menninger K, Kunkler A et al. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with cyclosporine Neoral or with RAD. Transpl Immunol 2000: 8: 177-187.
3. Miyamoto T, Matsumori A, Hwang M-W, Nishio R, Ito H, Sasayama S. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol 2001: 37: 1713-1718.
4. Brinkmann V, Wilt C, Kristofic C et al. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 2001: 33: 3078-3080.
5. Fujino M, Li XK, Guo L et al. T-cell apoptosis triggered by fty720 via mitochondrial pathway. Transplant Proc 2001: 33: 3084-3085.
6. Brinkmann V, Davis MD, Heise C et al. The immune modulator fty720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002: 277: 21453-21457.
7. Yang Z, Chen M, Fialkow LB et al. The immune modulator FTY720 prevents autoinumme diabetes in nonobese diabetic mice. Clin Immunol 2003: 107: 30-35.
8. Kover KL, Geng Z, Hess DM, Benjamin CD, Moore WV. Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DRBB rat. Diabetes 2000: 49: 1666-1670.
9. Greiner DL, Mordes JP, Handler ES, Angelillo M, Nakamura N, Rossini AA. Depletion of RT6.1 + T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med 1987: 166: 461-475.
10. Nikolova Z, Hof A, Baumlin Y, Hof RP. Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to Lewis heart and skin transplantation models. Transpl Immunol 2001: 2: 267-277.
11. Nikolova Z, Hof A, Baumlin Y, Hof RP. Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model. Transplantation 2001: 72: 168-171.
12. Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001: 72: 764-769.
13. Brinkmann V, Chen S, Feng L, Pinschewer D, Nikolova Z, Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001: 33: 530-531.
14. Bohler T, Waiser J, Schurz M et al. FTY720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism. Transplant Int 2000: 13: S311-S313.
15. Budde K, Schmouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002: 13: 1073-1083.
16. Yamasaki T, Inoue K, Hayashi H et al. Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. Cell Transplant 1998: 7: 403-406.
17. Fu F, Hu S, Ki S et al. FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. Transplant Proc 2001: 33: 672-673.
18. Suzuki K, Yan H, Li X-K, Amemiya H, Suzuki S, Hiromitsu K. Prevention of experimentally induced autoimmune type 1 diabetes in rats by the new immunosuppressive reagents FTY720. Transplant Proc 1998: 30: 1044-1045.
19. Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 2002: 74: 1684-1686.
20. Okazaki H, Hirata D, Kamimura T et al. Effects of FTY720 in MRL-1pr/1pr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 2002: 29: 707-716.
21. Moore WV, Chu W, Tong PY et al. Prevention of autoimmune diabetes in the DRBB rat by CD40/154 blockade. J Autoimmune 2002: 19: 139-145.
22. Henning G, Ohl L, Junt T et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 2001: 194: 1875-1881.
23. Chen S, Bacon KB, Garcia G et al. FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. Transplant Proc 2001: 33: 3057-3063.